Piper Jaffray Downgrades Arrowhead Research (ARWR) to Neutral
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices slip as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Arrowhead Research (ARWR) PT Slashed to $2 at Jefferies
November 30, 2016 8:12 AM ESTJefferies analyst Eun Yang lowered his price target on Arrowhead Research (NASDAQ: ARWR) to $2.00 (from $5.00) while maintaining a Hold rating after the company discontinues its EX1-based clinical programs (ARC-520, ARC-521, ARC-AAT) given likely "substantial" delays due to need for add'l non-clinical studies due... More
Arrowhead Research (ARWR) to Discontinue ARC-520, ARC-521, and ARC-AAT Development; Will Cut Workforce
November 29, 2016 4:04 PM ESTArrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the companys new proprietary subcutaneous (subQ) and extra-hepatic delivery systems. Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. The company is hosting a conference call at 4:30 p.m. EST to discuss this decision.
Arrowhead remains committed to finding therapeutic options for patients with chronic hepatitis B (HBV) infection and alpha-1 antitrypsin deficiency (AATD). The company intends to advance to the... More